Sarah Meredith, Professor of Clinical Trials

Sarah is a clinical epidemiologist and public health physician with a particular interest in the safety and efficacy of medicines, and the design and conduct of studies to provide better evidence to support clinical and public health decisions about their use.

She joined the MRC Clinical Trials Unit in 2000 in the Division Without Portfolio. She had the remit of supporting the development of clinical trials in areas in which there were important questions but a lack of necessary infrastructure or expertise to design, conduct or analyses the clinical trials needed to answer those questions. As a result, she has collaborated on trials in a range of different clinical fields, particularly tuberculosis, dermatology (with the UK Dermatology Clinical Trials Network) and transfusion medicine (as part of the MRC/NHSBT Clinical Studies Unit). Her current focus is on improving the treatment and management of tuberculosis globally, particularly drug-resistant tuberculosis.

She previously worked at the National Heart and Lung Institute on respiratory disease surveillance, and in the Department of Preventive Medicine at Vanderbilt University where she gained experience in pharmaco-epidemiology.

Selected publications

Ray WA, Murray KT, Meredith S, Narasimhulu S, Hall K, Stein M. Erythromycin and the risk of sudden death from cardiac causes. NEJM 2004; 351:1089-1096.

Ray WA, Taylor JA, Brown AK, Giddeon P, Hall K, Arbogast P, Meredith S. Prevention of fall-related injuries in long-term care: a randomized controlled trial of staff education. Archives of Internal Medicine 2005; 165:2293-2298.

Elebute MO, Choo L, Mora A, Macrury C, Llewelyn C, Purohit S, Hicks V, Casey C, Malfroy M, Deary A, Reed T, Meredith S, Manson L, Williamson LM. Transfusion of prion-filtered red cells does not increase the rate of alloimmunization or transfusion reactions in patients: results of the UK trial of prion-filtered versus standard red cells in surgical patients (PRISM A). British Journal of Haematology. 2013 160; 5 701-708.

Thomas KS, Crook AM, Nunn AJ, Foster KA, Mason JM , Chalmers JR, Nasr IS , Brindle RJ, English J, Meredith SK, Reynolds NJ, de Berker D, Mortimer PS and Williams HC on behalf of the UK Dermatology Clinical Trials Network’s PATCH I Trial Team. Penicillin to prevent leg cellulitis recurrence: randomized controlled trial; NEJM 2013 368;18 1695-1703.

Gillespie SG, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, Pappas F, Phillips PPJ, Nunn AJ for the REMoxTB Consortium. Two Four-Month Moxifloxacin-based Regimens for Drug-Sensitive Tuberculosis. NEJM 2014; 371: 1577-1587.

Nunn, A. J., Rusen, I. D., Van Deun, A., Torrea, G., Phillips, P. J. P., Chiang, C. -Y., Meredith, S.K.. The Evaluation of a Standardised Treatment Regimen of anti-Tuberculosis Drugs for Patients with MDR-TB (STREAM): study protocol for a randomised controlled trial. TRIALS 2014.

Sydes, M. R., Johnson, A. L., Meredith, S. K., Rauchenberger, M., South, A., & Parmar, M. K. B. Sharing data from clinical trials: the rationale for a controlled access approach. TRIALS 2015, 16. doi:10.1186/s13063-015-0604-6

Tweed, C. D., Wills, G. H., Crook, A. M., Dawson, R., Diacon, A. H., Louw, C. E. (2018). Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study. BMC Medicine, 2018; 16 (1), 46. doi:10.1186/s12916-018-1033-7

Tweed, C. D., Crook, A. M., Amukoye, E. I., Dawson, R., Diacon, A. H., Hanekom, M.,  Toxicity associated with tuberculosis chemotherapy in the REMoxTB study. BMC infectious diseases, 2018;18 (1), 317. doi:10.1186/s12879-018-3230-6

Nunn AJ, Phillips PPJ, Meredith SK, Chiang C-Y, Conradie F, Dalai D, van Deun A, Dat P-T, Lan N, Master I, et al. A Trial of a Shorter Regimen for Rifampin-Resistant TuberculosisNew England Journal of Medicine 28 Mar 2019

Madan JJ, Rosu L, Tefera MG, van Rensburg C, Evans D, Langley I, et al. Economic evaluation of short treatment for multidrug-resistant tuberculosis, Ethiopia and South Africa: the STREAM trial. Bulletin of the World Health Organization. 2020;98(5):306.

Research Interests

  • Improvement of tuberculosis treatment and management
  • Support of clinical trials in underdeveloped areas
  • Risk-based approaches to clinical trial conduct.

Research Areas

Related Studies

IRIS Profile